Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

Journal of Clinical Oncology

Volumn 26, Issue 28, 2008, Pages 4572-4578

  Hahn, Olwen M ^a   Yang, Cheng ^a   Medved, Milica ^a   Karczmar, Gregory ^a   Kistner, Emily ^a   Karrison, Theodore ^a   Manchen, Elizabeth ^a   Mitchell, Myrosia ^a   Ratain, Mark J ^a   Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GADODIAMIDE; PLACEBO; SORAFENIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRY SKIN; FACE ERYTHEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZENESULFONATES; CARCINOMA, RENAL CELL; CONTRAST MEDIA; DOUBLE-BLIND METHOD; FEMALE; GADOLINIUM DTPA; HUMANS; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLACEBOS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PYRIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 53749092242     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.5655     Document Type: Article

References (31)

1. Escudier B, Koralewski P, Pluzanska A, et al: A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 25:2s, 2007 (suppl; abstr 3),
2. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
3. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
4. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
5. Padhani AR: Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions. J Magn Reson Imaging 16:407-422, 2002
6. Checkley D, Tessier JJ, Kendrew J, et al: Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89:1889-1895, 2003
7. Barrett T, Brechbiel M, Bernardo M, et al: MRI of tumor angiogenesis. J Magn Reson Imaging 26:235-249, 2007
8. Drevs J, Muller-Driver R, Wittig C, et al: PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62:4015-4022, 2002
9. Kiessling F, Morgenstern B, Zhang C: Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem 14:77-91, 2007
10. Stevenson JP, Rosen M, Sun W, et al: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428-4438, 2003
11. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003
12. O'Dwyer PJ, Gallagher M, Schwartz B, et al: Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma. J Clin Oncol 23:193s, 2005 (suppl; abstr 3005)
13. Liu G, Rugo HS, Wilding G, et al: Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study. J Clin Oncol 23:5464-5473, 2005
14. Mross K, Drevs J, Muller M, et al: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 41:1291-1299, 2005
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Evelhoch J, Garwood M, Vigneron D, et al: Expanding the use of magnetic resonance in the assessment of tumor response to therapy: Workshop report. Cancer Res 65:7041-7044, 2005
17. Leach MO, Brindle KM, Evelhoch JL, et al: The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 92:1599-1610, 2005
18. Medved M, Karczmar G, Yang C, et al: Semi-quantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging 20:122-128, 2004
19. Tofts PS, Brix G, Buckley DL, et al: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 10:223-232, 1999
20. Yang C, Karczmar GS, Medved M, et al: Multiple reference tissue method for contrast agent arterial input function estimation. Magn Reson Med 58:1266-1275, 2007
21. Bland JM, Altman DG: Measurement error proportional to the mean. BMJ 313:106, 1996
22. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006
23. Strumberg D, Awada A, Hirte H, et al: Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 42:548-556, 2006
24. Clark JW, Eder JP, Ryan D, et al: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors Clin Cancer Res 11:5472-5480, 2005
25. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972, 2005
26. Conrad C, Friedman H, Reardon D, et al: A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 22:110s, 2004 (suppl; abstr 1512)
27. Griebel J, Mayr NA, de Vries A, et al: Assessment of tumor microcirculation: A new role of dynamic contrast MR imaging. J Magn Reson Imaging 7:111-119, 1997
28. Tofts PS, Kermode AG: Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging: 1. Fundamental concepts. Magn Reson Med 17:357-367, 1991
29. Parker GJ, Tanner SF, Leach MO: Pitfalls in the measurement of tissue permeability over short-scales using a low temporal resolution blood input function. Proceedings of the 4th Annual Meeting of International Society of Magnetic Resonance in Medicine, New York, NY, April 27-May 3, 1996
30. Li X, Rooney WD, Springer CS Jr: A unified magnetic resonance imaging pharmacokinetic theory: Intravascular and extracellular contrast reagents. Magn Reson Med 54:1351-1359, 2005
31. St Lawrence KS, Lee TY: An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J Cereb Blood Flow Metab 18:1365-1377, 1998